Scientific Director

Press Tab to Move to Skip to Content Link

Select how often (in days) to receive an alert:

The Consortium for Clinical Research and Innovation, Singapore (CRIS) brings together six national R&D, clinical translation and service programmes to advance clinical research and innovation for Singapore and establish important capabilities for a future-ready healthcare system. The Business Entities under CRIS include:

• Singapore Clinical Research Institute (SCRI)
• Advanced Cell Therapy and Research Institute, Singapore (ACTRIS)
• Cardiovascular Disease National Collaborative Enterprise (CADENCE)

Together, CRIS makes a positive difference to Singapore patients and researchers by ensuring that these clinical research platforms and programmes are at the cutting edge of capability development and innovation. If you are as passionate as we are in clinical trials and research, we want you

STCC; a nationally coordinated consortium to synergise cancer research capabilities in Singapore, brings together unmatched basic, clinical, and translational talent in Singapore to create globally significant peaks of excellence in selected Asian cancers.

STCC's five joint platforms – Cancer Clinical Trials and Investigational Medicine Units, Cancer Databases and Tissue Banks, Translational Research Integration and Support, Business Intelligence and Development, and Impact and Population Health – provide an enabling research and innovation environment driven to foster translational research and meaningful outcomes for society.

Through collaborative relationships with our partner institutions (comprising of National Cancer Centre Singapore (NCCS), National University Cancer Institute, Singapore (NCIS), National University Hospital (NUH), National University of Singapore (NUS) and Tan Tock Seng Hospital (TTSH)), and by capitalizing on the strengths of industry and academia, STCC is uniquely poised to develop initiatives that are aligned with Singapore's goals in value-based healthcare innovation and economic value creation.

STCC is a business unit of the Consortium for Clinical Research and Innovation, Singapore (CRIS), and is supported by the National Research Foundation, Singapore (NRF) and the Singapore Ministry of Health through the National Medical Research Council (NMRC) Office, MOH Holdings Pte Ltd.

About the Role

STCC seeks a visionary and collaborative Scientific Director to lead its scientific strategy and integration. Reporting to the Executive and Co-Directors, the Scientific Director will steer the consortium’s translational research direction, align efforts across tumour-specific peaks of excellence, and foster synergy across STCC’s data, biobanking, and clinical trial platforms.

Key Responsibilities

• Provide strategic scientific leadership and vision across STCC’s programmes, platforms, and partnerships.
• Drive prioritisation and integration of translational research initiatives across academic and industry collaborators.
• Champion scientific rigor and innovation across the research pipeline—from discovery to population impact.
• Serve as a key liaison with principal investigators, industry, and funding agencies to shape national and international partnerships.
• Guide the development and refinement of data- and specimen-driven research infrastructure, including the STCC Research Warehouse and Cancer Data Commons.

Qualifications

• MD, PhD, or equivalent with a strong track record in oncology research and leadership.
• Demonstrated ability to lead multi-institutional, multidisciplinary research programmes.
• Experience in building translational pipelines, clinical research networks, or national research infrastructure.
• Strong communication and stakeholder engagement skills.

What you need to know

Successful candidate will be offered a 3-year renewable contract. We regret that only shortlisted candidates will be contacted. For more information about CRIS and the Business Entities, visit our websites below:

Join us in shaping the future of cancer research and impact in Singapore and the region.